[e-farmacos] WHO Drug Information Vol 19, No. 4, 2005

["Canas, Martin" <macanas@netverk.com.ar>]

Estimadas y estimados,

Esta disponible el WHO Drug Information Vol 19, No. 4, 2005

con el siguiente contenido:

Drug Management
Avian influenza: impact on health programmes 273
Influenza antiviral medicinal products for potential use during a pandemic
274

Safety and Efficacy Issues
Safety challenges of preventing malaria during pregnancy 286
WHO International Drug Monitoring Programme: 28th meeting 287
Statins and memory loss 288
New safety information on long-acting beta-2 agonists 289
Meningococcal vaccine and Guillain Barre syndrome 290
Trastuzumab and possible cardiotoxicity 291
Trastuzumab: interim treatment recommendations 291
Oseltamivir paediatric adverse events 291
Duloxetine hydrochloride and hepatic effects 292
Intrathecal baclofen: incidents with implantable drug pump system 292
Ibritumomab tiuxetan therapeutic regimen: cutaneous reactions 293
Interactions with implantable medical devices 293
Liquid chemical polymer and serious adverse events 294
Atomoxetine and suicidal thinking in children and adolescents 294
Paroxetine: first trimester exposure and congenital malformations 295

Access to Medicines
Canada and the "Jean Chrétien Pledge to Africa" 296
Regulatory Action and News
Safety update on paediatric use of oseltamivir 301
Influenza virus composition for 2006 southern hemisphere winter 301
International biosafety guidelines for influenza vaccine production 301
Veralipride: withdrawal following review of risk/benefit 302
Pemoline: liver injury risk and market withdrawal 302
Nelarabine approved for leukaemia and lymphoma 303
EMEA proposes new, faster scientific advice procedure 303
Withdrawal of Infanrix HepB® 303
Precautionary suspension of Hexavac®: lowered immunogenicity 304
Environmental risk assessment for human and veterinary medicinal products
304

Recent Publications, Information and Events
Promoting drug use in the community 306
Registration of fixed dose combinations 306
Sources and prices of HIV medicines and diagnostics 306
Screening guidelines for women exposed to DES in utero 307
The Blue Guide on advertising 307
Chronic airways disease guide 308
Priority medicines for Europe and the world 308
International Pharmacopoeia
Monograph for oral powders 309
Launch of new medicines website 312
Proposed International Nonproprietary Names: List 94

disponible en:
http://www.who.int/druginformation/vol19num4_2005/DI19-4.pdf

Saludos,

Martin

Martin Canas
GAPURMED
La Plata 
(Argentina)
macanas@netverk.com.ar